Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

Inclusion Criteria: * Metastatic or unrectable sarcoma that has either relapsed or was refractory to at leat 1 prior chemotherapy or immunotherapy regimen and for which no standard approved therapy exists * Must not be eligible for another CytRx-sponsored clinical trial * Able to provide complete medical records for review by the CytRx Medical Monitor * Able to receive treatment at a site that is participating or has participated in another CytRx-sponsored aldoxorubicin trial * Capable of providing informed consent and complying with trial procedures * ECOG performance status 0-2 * Measurable or evaluable tumor lesions according to RECIST 1.1 criteria * Women must not be able to become pregnant (eg post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study * Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating Exclusion Criteria: * Chemotherapy, palliative surgery and/or radiation treatment less than 30 days prior to screening for non-target lesion * Exposure to any investigational agent within 30 days of screening * Central nervous system metastases that are symptomatic * Laboratory values: Screening serum creatinine \>1.5×ULN, ALT \>3×ULN, or \>5×ULN if liver metastases are present, total bilirubin \>3×ULN, ANC \<1,500/mm3, platelet concentration \<100,000/mm3, hematocrit level \<25% for females or \<27% for males, coagulation tests (PT, PTT, INR) \>1.5×ULN * Anion gap \> 16 meq/L or arterial or venous blood pH \< 7.30. * Clinically evident congestive heart failure \> class II of the New York Heart Association (NYHA) guidelines * Current serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V * Baseline QTc \>470 msec and/or previous history of QT prolongation while taking other medications. Concomitant use of medications associated with a high incidence of QT prolongation is not allowed * History or signs of active coronary artery disease with or without angina pectoris. * Serious myocardial dysfunction defined scintigraphically (eg MUGA, myocardial scintigram) or ultrasound determined absolute LVEF \<45% of predicted * History of HIV infection * Active, clinically signifiant serious infection requiring treatment with antibiotics, anti-virals or anti-fungals * Major surgery within 3 weeks prior to enrollment * Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results